Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Vaginal cancer is rare cancer that occurs in the vagina. Its symptoms include watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation, and pelvic pain, vaginal bleeding.

The Vaginal Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects.

Vaginal Cancer Pipeline Products Market Segmentation by Targets

The key targets in the Vaginal Cancer pipeline products market are Human Papillomavirus Protein E6, Human Papillomavirus Protein E7, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Major Capsid Protein L1, Transforming Growth Factor Beta, Cadherin 3, Cells Expressing Human Papillomavirus Protein E6, and others.

Vaginal Cancer Pipeline Products Market Analysis by Targets

Vaginal Cancer Pipeline Products Market Analysis by Targets

For more target insights into the Vaginal Cancer pipeline products market, download a free report sample

Vaginal Cancer Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Vaginal Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Transforming Growth Factor Beta Inhibitor, Cadherin 3 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6,  Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, DNA Synthesis Inhibitor, and others.

Vaginal Cancer Pipeline Products Market Analysis by Mechanisms of Action

Vaginal Cancer Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Vaginal Cancer pipeline products market, download a free report sample

Vaginal Cancer Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Vaginal Cancer pipeline products market are intravenous, intramuscular, subcutaneous, intraperitoneal, oral, intratumor, intravenous drip, intravesical, parenteral, and others.

Vaginal Cancer Pipeline Products Market Analysis by Routes of Administration

Vaginal Cancer Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Vaginal Cancer pipeline products market, download a free report sample

Vaginal Cancer Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Vaginal Cancer pipeline products market are monoclonal antibody, subunit vaccine, small molecule, recombinant vector vaccine, cell therapy, fusion protein, monoclonal antibody conjugated, DNA vaccine, gene-modified cell therapy, oncolytic virus, and vaccine.

Vaginal Cancer Pipeline Products Market Analysis by Molecule Types

Vaginal Cancer Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the Vaginal Cancer pipeline products market, download a free report sample

Vaginal Cancer Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Vaginal Cancer pipeline products market are AstraZeneca Plc, Merck & Co Inc, Bristol-Myers Squibb Co, Hookipa Pharma Inc, Merck KGaA, Pionyr Immunotherapeutics Inc, Privo Technologies Inc, Shanghai Bovax Biotechnology Co Ltd, SQZ Biotechnologies Co, and Beijing Kangle Guardian Biotechnology Co Ltd.

Vaginal Cancer Pipeline Products Market Analysis by Companies

Vaginal Cancer Pipeline Products Market Analysis by Companies

To know more about the leading players in the Vaginal Cancer pipeline products market, download a free report sample

Vaginal Cancer Pipeline Products Market Report Overview

Key Targets Human Papillomavirus Protein E6, Human Papillomavirus Protein E7, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Major Capsid Protein L1, Transforming Growth Factor Beta, Cadherin 3, Cells Expressing Human Papillomavirus Protein E6, and Others
Key Mechanisms of Action Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Transforming Growth Factor Beta Inhibitor, Cadherin 3 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, DNA Synthesis Inhibitor, and Others
Key Routes of Administration Intravenous, Intramuscular, Subcutaneous, Intraperitoneal, Oral, Intratumor, Intravenous Drip, Intravesical, Parenteral, and Others
Key Molecule Type Monoclonal Antibody, Subunit Vaccine, Small Molecule, Recombinant Vector Vaccine, Cell Therapy, Fusion Protein, Monoclonal Antibody Conjugated, DNA Vaccine, Gene-Modified Cell Therapy, Oncolytic Virus, and Vaccine
Leading Companies AstraZeneca Plc, Merck & Co Inc, Bristol-Myers Squibb Co, Hookipa Pharma Inc, Merck KGaA, Pionyr Immunotherapeutics Inc, Privo Technologies Inc, Shanghai Bovax Biotechnology Co Ltd, SQZ Biotechnologies Co, and Beijing Kangle Guardian Biotechnology Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Vaginal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vaginal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vaginal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Vaginal Cancer (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vaginal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vaginal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AstraZeneca Plc
Beijing Kangle Guardian Biotechnology Co Ltd
Beijing Kangleweishi Biotechnology Co Ltd
Bristol-Myers Squibb Co
Chengdu Institute of Biological Products Co Ltd
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Hookipa Pharma Inc
ISA Pharmaceuticals BV
Merck & Co Inc
Merck KGaA
Ology Bioservices Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Perseus Proteomics Inc
Pionyr Immunotherapeutics Inc
Precigen Inc
Privo Technologies Inc
RemeGen Co Ltd
Shanghai Bovax Biotechnology Co Ltd
Shanghai Zerun Biotechnology Co Ltd
SinoCelltech Group Ltd
SQZ Biotechnologies Co
Suzhou Neupharma Co Ltd
Transcenta Holding Ltd
Transgene SA
Turnstone Biologics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vaginal Cancer – Overview

Vaginal Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vaginal Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vaginal Cancer – Companies Involved in Therapeutics Development

AstraZeneca Plc

Beijing Kangle Guardian Biotechnology Co Ltd

Beijing Kangleweishi Biotechnology Co Ltd

Bristol-Myers Squibb Co

Chengdu Institute of Biological Products Co Ltd

Eisai Co Ltd

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

Hookipa Pharma Inc

ISA Pharmaceuticals BV

Merck & Co Inc

Merck KGaA

Ology Bioservices Inc

Ono Pharmaceutical Co Ltd

PDS Biotechnology Corp

Perseus Proteomics Inc

Pionyr Immunotherapeutics Inc

Precigen Inc

Privo Technologies Inc

RemeGen Co Ltd

Shanghai Bovax Biotechnology Co Ltd

Shanghai Zerun Biotechnology Co Ltd

SinoCelltech Group Ltd

SQZ Biotechnologies Co

Suzhou Neupharma Co Ltd

Transcenta Holding Ltd

Transgene SA

Turnstone Biologics Inc

Vaginal Cancer – Drug Profiles

adavosertib – Drug Profile

Product Description

Mechanism Of Action

bevacizumab – Drug Profile

Product Description

Mechanism Of Action

bintrafusp alfa – Drug Profile

Product Description

Mechanism Of Action

cisplatin – Drug Profile

Product Description

Mechanism Of Action

decitabine – Drug Profile

Product Description

Mechanism Of Action

disitamab vedotin – Drug Profile

Product Description

Mechanism Of Action

durvalumab – Drug Profile

Product Description

Mechanism Of Action

durvalumab + tremelimumab – Drug Profile

Product Description

Mechanism Of Action

HB-201 – Drug Profile

Product Description

Mechanism Of Action

HB-202 – Drug Profile

Product Description

Mechanism Of Action

HPV-16 E7 – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus (9 valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus (9-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 16, 18, 58] (trivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58,59 and 68] (11-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58] (9-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

ipilimumab + nivolumab – Drug Profile

Product Description

Mechanism Of Action

M-9241 – Drug Profile

Product Description

Mechanism Of Action

MEDI-0457 – Drug Profile

Product Description

Mechanism Of Action

nivolumab – Drug Profile

Product Description

Mechanism Of Action

NTO-1151 – Drug Profile

Product Description

Mechanism Of Action

Oncolytic Virus to Target E6 and E7 for Human Papillomavirus (HPV) Associated Solid Tumors – Drug Profile

Product Description

Mechanism Of Action

PDS-0101 – Drug Profile

Product Description

Mechanism Of Action

peltopepimut-s – Drug Profile

Product Description

Mechanism Of Action

pembrolizumab – Drug Profile

Product Description

Mechanism Of Action

PPMX-T002 – Drug Profile

Product Description

Mechanism Of Action

PRGN-2009 – Drug Profile

Product Description

Mechanism Of Action

PRV-211 – Drug Profile

Product Description

Mechanism Of Action

PY-159 – Drug Profile

Product Description

Mechanism Of Action

PY-314 – Drug Profile

Product Description

Mechanism Of Action

RX-208 – Drug Profile

Product Description

Mechanism Of Action

SCT-1000 – Drug Profile

Product Description

Mechanism Of Action

SQZ-AACs (Oncology) – Drug Profile

Product Description

Mechanism Of Action

SQZ-APCs (Oncology) – Drug Profile

Product Description

Mechanism Of Action

tipapkinogene sovacivec – Drug Profile

Product Description

Mechanism Of Action

TST-005 – Drug Profile

Product Description

Mechanism Of Action

Vaginal Cancer – Dormant Projects

Vaginal Cancer – Product Development Milestones

Featured News & Press Releases

Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers

Jun 17, 2015: GARDASIL9: New HPV vaccine approved in the European Union

Apr 01, 2015: Merck’s HPV Vaccine, GARDASIL 9, now available in Canada

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Vaginal Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Vaginal Cancer – Pipeline by AstraZeneca Plc, 2022

Vaginal Cancer – Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022

Vaginal Cancer – Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022

Vaginal Cancer – Pipeline by Bristol-Myers Squibb Co, 2022

Vaginal Cancer – Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022

Vaginal Cancer – Pipeline by Eisai Co Ltd, 2022

Vaginal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Vaginal Cancer – Pipeline by Gilead Sciences Inc, 2022

Vaginal Cancer – Pipeline by Hookipa Pharma Inc, 2022

Vaginal Cancer – Pipeline by ISA Pharmaceuticals BV, 2022

Vaginal Cancer – Pipeline by Merck & Co Inc, 2022

Vaginal Cancer – Pipeline by Merck KGaA, 2022

Vaginal Cancer – Pipeline by Ology Bioservices Inc, 2022

Vaginal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, 2022

Vaginal Cancer – Pipeline by PDS Biotechnology Corp, 2022

Vaginal Cancer – Pipeline by Perseus Proteomics Inc, 2022

Vaginal Cancer – Pipeline by Pionyr Immunotherapeutics Inc, 2022

Vaginal Cancer – Pipeline by Precigen Inc, 2022

Vaginal Cancer – Pipeline by Privo Technologies Inc, 2022

Vaginal Cancer – Pipeline by RemeGen Co Ltd, 2022

Vaginal Cancer – Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022

Vaginal Cancer – Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022

Vaginal Cancer – Pipeline by SinoCelltech Group Ltd, 2022

Vaginal Cancer – Pipeline by SQZ Biotechnologies Co, 2022

Vaginal Cancer – Pipeline by Suzhou Neupharma Co Ltd, 2022

Vaginal Cancer – Pipeline by Transcenta Holding Ltd, 2022

Vaginal Cancer – Pipeline by Transgene SA, 2022

Vaginal Cancer – Pipeline by Turnstone Biologics Inc, 2022

Vaginal Cancer – Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development for Vaginal Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Vaginal Cancer pipeline products market?

    The key targets in the Vaginal Cancer pipeline products market are Human Papillomavirus Protein E6, Human Papillomavirus Protein E7, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Major Capsid Protein L1, Transforming Growth Factor Beta, Cadherin 3, Cells Expressing Human Papillomavirus Protein E6, and others.

  • What are the key mechanisms of action in the Vaginal Cancer pipeline products market?

    The key mechanisms of action in the Vaginal Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Transforming Growth Factor Beta Inhibitor, Cadherin 3 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6,  Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, DNA Synthesis Inhibitor, and others.

  • What are the key routes of administration in the Vaginal Cancer pipeline products market?

    The key routes of administration in the Vaginal Cancer pipeline products market are intravenous, intramuscular, subcutaneous, intraperitoneal, oral, intratumor, intravenous drip, intravesical, parenteral, and others.

  • What are the key molecule types in the Vaginal Cancer pipeline products market?

    The key molecule types in the Vaginal Cancer pipeline products market are monoclonal antibody, subunit vaccine, small molecule, recombinant vector vaccine, cell therapy, fusion protein, monoclonal antibody conjugated, DNA vaccine, gene-modified cell therapy, oncolytic virus, and vaccine.

  • Which are the leading companies in the Vaginal Cancer pipeline products market?

    Some of the leading companies in the Vaginal Cancer pipeline products market are AstraZeneca Plc, Merck & Co Inc, Bristol-Myers Squibb Co, Hookipa Pharma Inc, Merck KGaA, Pionyr Immunotherapeutics Inc, Privo Technologies Inc, Shanghai Bovax Biotechnology Co Ltd, SQZ Biotechnologies Co, and Beijing Kangle Guardian Biotechnology Co Ltd.

Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.